1-叔丁基-3-苯基-1H-吡唑 | 1269293-29-9

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-叔丁基-3-苯基-1H-吡唑
• 英文名称: 1-tert-butyl-3-phenyl-1H-pyrazole
• 英文别名: 1-tert-butyl-3-phenylpyrazole
• CAS: 1269293-29-9
• 化学式: C₁₃H₁₆N₂
• 分子量: 200.28
• InChiKey: UECGAZMPLYGHSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20160095858A1

  公开（公告）日：2016-04-07

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明涉及一种具有以下化学式I的化合物： 或其药用可接受的盐，其中R 1 ，R 2 ，R 3 ，W，X，Y，Z，n，o，p和q在此处定义，用于治疗CFTR介导的疾病，如囊性纤维化。本发明还涉及药物组合物、治疗方法和相关工具包。
• PAR2-modulating compounds and their use
  申请人：Olsson Roger

  公开号：US20070123508A1

  公开（公告）日：2007-05-31

  This invention relates to compounds, their uses for the elucidation of PAR2 activity and their uses for the treatment or prevention of diseases or disorders related to PAR2 activity, wherein the compound has the general chemical structure:

  本发明涉及化合物，它们用于阐明PAR2活性以及用于治疗或预防与PAR2活性相关的疾病或障碍，其中该化合物具有一般化学结构：
• FUNGICIDAL AMIDES
  申请人：Hanagan Mary Ann

  公开号：US20100286147A1

  公开（公告）日：2010-11-11

  Disclosed are compounds of Formulae 1 and 1A (including all geometric and stereoisomers), N-oxides, and salts thereof, wherein R 1 , R 2 , A, G, M, W, Z 1 , X, J, J 1 and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

  本发明涉及公式1和1A（包括所有几何和立体异构体）、N-氧化物和其盐的化合物，其中R1、R2、A、G、M、W、Z1、X、J、J1和n如本公开说明书中所定义。本发明还涉及含有公式1化合物的组合物以及用于控制由真菌病原体引起的植物病害的方法，包括施用本发明的化合物或组合物的有效量。
• Modulators of cystic fibrosis transmembrane conductance regulator
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10258624B2

  公开（公告）日：2019-04-16

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明的特征是一种式 I 的化合物： 或其药学上可接受的盐，其中 R1、R2、R3、W、X、Y、Z、n、o、p 和 q 在本文中定义，用于治疗 CFTR 介导的疾病，如囊性纤维化。本发明还包括药物组合物、治疗方法及其试剂盒。
• Potassium channel modulators
  申请人：Cadent Therapeutics, Inc.

  公开号：US10774064B2

  公开（公告）日：2020-09-15

  Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.

  本发明提供了式 (I) 的新型化合物：及其药学上可接受的盐类，它们可用于治疗各种可受钾通道调节影响的疾病、失调或病症。还提供了包含式（I）新型化合物及其药学上可接受的盐的药物组合物，以及将其用于治疗一种或多种与钾通道相关的疾病、失调或病症的方法。